Abu Dhabi’s healthcare sector is taking a significant step forward by integrating advanced technology into patient care. The Department of Health – Abu Dhabi, Eli Lilly Pharmaceuticals, and Eli Lilly Drugstore LLC have signed a memorandum of understanding to enhance cooperation in developing treatments for obesity and Alzheimer’s disease. This partnership focuses on employing artificial intelligence technologies and advanced clinical care to explore the creation of an innovative healthcare model. The official signing took place during the Biotechnology Innovation Organization World Conference 2026, held in San Diego, USA.
The collaboration is structured around two main strategic tracks aimed at improving patient outcomes. The first track involves forming a joint working group to design and develop an AI-powered care model for obesity and cardiometabolic diseases. This model is specifically tailored to the needs of Abu Dhabi’s population. It will utilize the emirate’s population health data combined with Eli Lilly’s therapeutic expertise in metabolic diseases. The objective is to support the development of advanced models for risk classification and the provision of appropriate personalized therapeutic interventions. This approach aims to provide advanced, predictive, and personalized metabolic care designed to suit the local community.
The second strategic track focuses on studying the establishment of a global center of excellence for Alzheimer’s disease. This effort builds upon the existing cooperation between the Department of Health – Abu Dhabi and Eli Lilly in the field of neurodegenerative diseases. The proposed center aims to accelerate early detection of the disease and promote biomarker-based diagnosis. This contributes to enhancing early detection and expanding the scope of integrated digital cognitive screening. Furthermore, it seeks to expand access to the latest disease-modifying treatments. By developing care pathways across the full spectrum of Alzheimer’s disease, the partners aim to address the complex needs of patients through a comprehensive approach.
Frequently asked questions
What is the Department of Health Abu Dhabi partnership with Eli Lilly for?
The Department of Health – Abu Dhabi and Eli Lilly have partnered to develop AI-powered treatments for obesity and Alzheimer's disease.
Where was the Abu Dhabi Health and Eli Lilly agreement signed?
The agreement was signed during the Biotechnology Innovation Organization World Conference 2026 in San Diego, USA.
How will AI be used in Abu Dhabi's obesity care?
AI will be used to design and develop a care model for obesity and cardiometabolic diseases, utilizing population health data and therapeutic expertise.
